1092 related articles for article (PubMed ID: 27856181)
41. Long non-coding RNA LINP1 promotes the malignant progression of prostate cancer by regulating p53.
Wu HF; Ren LG; Xiao JQ; Zhang Y; Mao XW; Zhou LF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4467-4476. PubMed ID: 30058678
[TBL] [Abstract][Full Text] [Related]
42. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
43. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.
Meng J; Wang LH; Zou CL; Dai SM; Zhang J; Lu Y
Med Sci Monit; 2017 Oct; 23():5176-5183. PubMed ID: 29084195
[TBL] [Abstract][Full Text] [Related]
44. Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells.
Xu X; Zhu Z; Xu Y; Tian S; Jiang Y; Zhao H
Oncol Rep; 2020 Dec; 44(6):2455-2464. PubMed ID: 33125130
[TBL] [Abstract][Full Text] [Related]
45. Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.
Zhang Y; Zhang M; Yu F; Lu S; Sun H; Tang H; Peng Z
J Exp Clin Cancer Res; 2015 Dec; 34():145. PubMed ID: 26626145
[TBL] [Abstract][Full Text] [Related]
46. HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.
Zhou X; Li Q; He J; Zhong L; Shu F; Xing R; Lv D; Lei B; Wan B; Yang Y; Wu H; Mao X; Zou Y
Oncotarget; 2017 Mar; 8(12):19342-19353. PubMed ID: 28038443
[TBL] [Abstract][Full Text] [Related]
47. Gelsolin-like actin-capping protein is associated with patient prognosis, cellular apoptosis and proliferation in prostate cancer.
Li T; Hong X; Zhao J; Teng Y; Zheng J; Chen H; Chen H; Li H
Biomark Med; 2016 Dec; 10(12):1251-1260. PubMed ID: 27924630
[TBL] [Abstract][Full Text] [Related]
48. Circular RNA circMBOAT2 promotes prostate cancer progression via a miR-1271-5p/mTOR axis.
Shi J; Liu C; Chen C; Guo K; Tang Z; Luo Y; Chen L; Su Y; Xu K
Aging (Albany NY); 2020 Jul; 12(13):13255-13280. PubMed ID: 32645691
[TBL] [Abstract][Full Text] [Related]
49. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
50. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
51. Reciprocal regulation of long noncoding RNAs THBS4‑003 and THBS4 control migration and invasion in prostate cancer cell lines.
Liu J; Cheng G; Yang H; Deng X; Qin C; Hua L; Yin C
Mol Med Rep; 2016 Aug; 14(2):1451-8. PubMed ID: 27357608
[TBL] [Abstract][Full Text] [Related]
52. Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.
Zhang H; Shen T; Zhang Z; Li Y; Pan Z
Med Sci Monit; 2019 Aug; 25():6418-6428. PubMed ID: 31451680
[TBL] [Abstract][Full Text] [Related]
53. IL-10 and PRKDC polymorphisms are associated with glioma patient survival.
Hu M; Du J; Cui L; Huang T; Guo X; Zhao Y; Ma X; Jin T; Li G; Song J
Oncotarget; 2016 Dec; 7(49):80680-80687. PubMed ID: 27811370
[TBL] [Abstract][Full Text] [Related]
54. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
[TBL] [Abstract][Full Text] [Related]
55. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
56. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
57. EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
Fan HT; Shi YY; Lin Y; Yang XP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7808-7815. PubMed ID: 31599405
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
Kong Q; Chen XS; Tian T; Xia XY; Xu P
Oncol Rep; 2017 Feb; 37(2):803-812. PubMed ID: 27959429
[TBL] [Abstract][Full Text] [Related]
59. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
60. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
